• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-p16 antibody :: Rabbit anti-Human p16 Polyclonal Antibody

Scan QR to view Datasheet
Catalog # MBS440018
Unit / Price
  0.2 mg  /  $240 +1 FREE 8GB USB
Immunohistochemistry (IHC)
Product Name

p16, Polyclonal Antibody

Popular Item
Also Known As

p16 (C20) Antibody

Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence Length
67
3D Structure
ModBase 3D Structure for Q208B5
Clonality
Polyclonal
Host
Rabbit
Species Reactivity
Human
Specificity
p16(C20) reacts with p16 of human origin by Western Blotting, Immunoprecipitation, and Immunohistochemistry. Western Blotting starting dilution: 1:200.
Form/Format
200 ug/ml of affinity purified rabbit IgG, p16 (C20) DB018, in 1ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Origin
p16 (C20) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human p16.
Product Details
Each vial contains 200ug/ml of affinity purified rabbit IgG, p16 (C20), in 1 ml PBS containing 0.1% sodium azide and 0.2% gelatin.
Immunogen
Synthetic peptide mapping to the carboxy terminus of human p16.
Competition Studies
A blocking peptide is also available MBS443018 for use in competititon studies. Each vial containing 100 ug of peptide in 0.5ml PBS with 0.1% sodium azide and 100 ug BSA.
Preparation and Storage
Store this product at 4 degree C, do not freeze. The product is stable for one year from the date of shipment.
Other Notes
Small volumes of anti-p16 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-p16 antibody
The progression through the cell cycle is regulated by cyclins and their cognate Cdks by promoting cell cycle transitions (1,2,3). This orderly progression can be inhibited by a family of proteins known as CDK inhibitors (CDIs) that bind to cyclin/Cdk complexes and halt cell division (3). p21 (also designated WAF1/Cip1) is one has been shown to inhibit the activity of each member of the cyclin/Cdk family and over expression of this protein inhibits the proliferation of mammalian cells (5). The expression of p21 is inducible by a wide range of stress stimuli and its transcription can be enhanced by p53 (6). Another member of the CDIs is p27 (also known as Kip1), which also sees up regulation in response to antimitogenic stimuli (7). The increased protein expression of p27 results in cellular arrest by binding to cyclin/Cdk complexes, like cyclin D1/Cdk4 (4,8). An additional CDI has been found to bind Cdk4 and Cdk6, p16 (INK4A), and when such complexes are formed, the progression of the cell cycle is halted (9). It has become increasingly clear that p16 is a very important tumor suppressor gene whose frequent loss occurs early in many human cancers. p16 is a major target in carcinogenesis that is rivaled in frequency only by p53 (10).
Applications Tested/Suitable for anti-p16 antibody
Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC)
Application Notes for anti-p16 antibody
p16(C20) DB018 reacts with p16 of human origin by western blotting, immunoprecipitation, and immunohistochemistry. Western blotting starting dilution: 1:200.

Immunohistochemistry (IHC) of anti-p16 antibody
anti-p16 antibody Immunohistochemistry (IHC) (IHC) image
NCBI/Uniprot data below describe general gene information for p16. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Related Accession #
NCBI Official Full Name
p16, partial
NCBI Official Synonym Full Names
cyclin-dependent kinase inhibitor 2A
NCBI Official Symbol
CDKN2A  [Similar Products]
NCBI Official Synonym Symbols
ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A
  [Similar Products]
NCBI Protein Information
cyclin-dependent kinase inhibitor 2A; CDK4 inhibitor p16-INK4; CDKN2A; alternative reading frame; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); multiple tumor suppressor 1
UniProt Protein Name
P16
UniProt Synonym Protein Names
P16
UniProt Gene Name
CDKN2A  [Similar Products]
UniProt Entry Name
Q208B5_HUMAN
NCBI Summary for p16
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
UniProt Comments for p16
p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Cell cycle regulation; Nucleolus; Tumor suppressor

Chromosomal Location of Human Ortholog: 9p21

Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; nucleus; cytosol

Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor binding; protein kinase binding

Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; caspase activation; negative regulation of immature T cell proliferation in the thymus; protein destabilization; transcription, DNA-dependent; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of DNA damage response, signal transduction by p53 class mediator; mitotic cell cycle; negative regulation of cell growth; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-pancreatic Cancer Syndrome
Product References and Citations for anti-p16 antibody
1.) Bihani T, Mason DX, Jackson TJ, Chen SC, Boettner B, Lin AW. 2004. Differential oncogenic Ras signaling and senescence in tumor cells. Cell Cycle 3(9):1201-7. 2.) Weebadda WK, Jackson TJ, Lin AW. 2005. Expression of p16(INK4A) variants in senescent human fibroblasts independent of protein phosphorylation. J Cell Biochem. Apr 15;94(6):1135-47.3.) Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic ras-induced senescence. Oncogene. 2004 Dec 9;23(57):9238-46.4.) Bihani T, Chicas A, Lo CP, Lin AW. 2007. Dissecting the senescence-like program in tumor cells activated by Ras signaling. J Biol Chem. Jan 26;282(4):2666-75.5.) Achour M, Jacq X, Rondé P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, Schini-Kerth VB, Bronner C. 2007. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene. Oct 15.

1. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4):805-816.2. Gartel AL, Serfas MS, Tyner AL. 1996. p21 - -negative regulator of the cell cycle. Proc Soc Exp Biol Med 213(2):138-149.3. Moller MB. 2000. p27 in cell cycle control and cancer. Leuk Lymphoma 39(1-2):19-27.4. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183(1):18-27.5. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366(6456):634.6. Gorospe M, Wang X, Holbrook NJ. 1999. Functional role of p21 during the cellular response to stress. Gene Expr 7(4-6):377-385.7. Slingerland J, Pagano M. 2000. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183(1):10-17.8. Toyoshima H, Hunter T. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78(1):67-74.9. Shapiro GI, Edwards CD, Rollins BJ. 2000. The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem Biophys 33(2):189-197.10. Liggett WH Jr, Sidransky D. 1998. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16(3):1197-1206.

Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000